Sage Therapeutics’ (SAGE) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE) in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a $28.00 target price on the biopharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. Royal Bank of Canada upped their target price on shares of Sage Therapeutics from $21.00 to $26.00 and gave the company a sector perform rating in a research report on Thursday, February 15th. Morgan Stanley upped their target price on shares of Sage Therapeutics from $20.00 to $22.00 and gave the company an equal weight rating in a research report on Wednesday, February 28th. StockNews.com upgraded shares of Sage Therapeutics from a sell rating to a hold rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. upped their target price on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an overweight rating in a research report on Tuesday, March 26th. Finally, Bank of America downgraded shares of Sage Therapeutics from a neutral rating to an underperform rating and cut their target price for the company from $24.00 to $14.00 in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $40.56.

Sage Therapeutics Price Performance

Shares of NASDAQ:SAGE opened at $12.57 on Wednesday. Sage Therapeutics has a 12 month low of $10.92 and a 12 month high of $59.99. The company’s 50-day moving average price is $20.06 and its two-hundred day moving average price is $20.96.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.73. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The firm had revenue of $77.97 million for the quarter, compared to analyst estimates of $60.15 million. During the same quarter in the prior year, the firm earned ($2.47) EPS. The company’s revenue was up 2621.5% on a year-over-year basis. On average, sell-side analysts expect that Sage Therapeutics will post -6.06 EPS for the current fiscal year.

Institutional Trading of Sage Therapeutics

Several hedge funds have recently bought and sold shares of SAGE. CWM LLC raised its holdings in Sage Therapeutics by 274.2% during the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 883 shares during the period. KBC Group NV acquired a new stake in Sage Therapeutics during the 4th quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. raised its holdings in Sage Therapeutics by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 748 shares during the period. MetLife Investment Management LLC bought a new position in shares of Sage Therapeutics during the 1st quarter worth approximately $34,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Sage Therapeutics by 74.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,050 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 2,148 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.